A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment.
Respir Med Case Rep
; 34: 101557, 2021.
Article
en En
| MEDLINE
| ID: mdl-34877251
ACQ, Asthma Control Questionnaire; BID, twice daily; Benralizumab; Biologics; Eosinophilia; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; FeNO, fractional exhaled nitric oxide; ICS, inhaled corticosteroid(s); IL, interleukin; IM, intramuscular; Ig, immunoglobulin; LABA, long-acting ß2-agonist; OCS, oral corticosteroid(s); Q4W, every 4 weeks; Q8W, every 8 weeks; QD, once daily; Quality of life; SAC, severe asthma center; SC, subcutaneously; Severe eosinophilic asthma
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Aspecto:
Patient_preference
Idioma:
En
Revista:
Respir Med Case Rep
Año:
2021
Tipo del documento:
Article
País de afiliación:
Reino Unido
Pais de publicación:
Reino Unido